We aimed to evaluate the safety of maternal Tdap we assessed health events by examining 29 the difference in birth and hospital-related outcomes of infants with and without fetal 30 exposure to Tdap. 31 This was a retrospective cohort study using linked administrative datasets. The study 32 population were all live-born infants in New Zealand (NZ) weighing at least 400 grams at 33 delivery and born to women who were eligible for the government funded, national-level 34 vaccination program in 2013. Infants were followed from birth up to one year of age. 35
Introduction 53
Pertussis vaccination programmes have had a dramatic impact on pertussis morbidity and 54 mortality, particularly for infants. The burden of severe morbidity and mortality now falls 55 primarily on infants too young to be vaccinated. However, a resurgence in disease is being 56 observed in many countries using acellular vaccines [1] and, to a lesser extent, countries 57 using whole-cell vaccines [2] . 58 Natural immunity to pertussis varies in terms of completeness and duration. Furthermore, 59 immunity via current acellular vaccines, while preventing clinical disease [3] , does not 60 prevent carriage or transmission [4, 5] . These issues pose challenges for the control of 61 pertussis. 62
Maternal immunisation as a strategy to prevent neonatal and infant mortality has been well 63 illustrated with the success of the World Health Organization (WHO)/UNICEF Neonatal 64 Tetanus Elimination programme in low-income settings. Following the implementation of 65 maternal tetanus immunisation programmes in at-risk populations, mortality from neonatal 66 tetanus declined by 94% [95% CI: 80, 98)] [6] . Evidence for the effectiveness of maternal 67 influenza vaccination in preventing influenza for the first months of life has also supported 68 the move to a maternal vaccination approach [7] . Since 2011, some countries, such as the 69 UK, have begun maternal pertussis immunisation [8, 9] and the strategy has proved highly 70 effective [10] [11] [12] [13] . 71
While there are no theoretical safety concerns about using inactive or subunit vaccines in 72 pregnant women [14] there were few empirical data available during the early years of these 73 programmes [15] . 74
Between 2011 and 2013, New Zealand (NZ) experienced the largest pertussis epidemic since 75 2000. The number of notified cases of pertussis rose dramatically from July 2011 and 76 remained high throughout 2012 and 2013, with rates of over 270/100,000 infants under one 77
year of age. Among notified cases in the less than six weeks of age group, 56% were 78 hospitalised, with 23% of these requiring multiple hospitalisations. Because of this disease 79 burden, a booster dose of acellular pertussis vaccine was recommended in 2012 and then 80 funded in 2013 for women between 28-38 weeks gestation. 81 This is the second paper that reports on outcomes from a retrospective data-linking study that 82 aimed to assess the safety of Tdap vaccine administered to pregnant women in NZ in 2013. 83 We previously reported the maternal outcomes [16] ; here, we report infant outcomes by 84 examining the difference in birth and hospital-related outcomes of infants with and without 85 fetal exposure to Tdap. 86 Methods 87
Study population and variables 88
The study population included all live-born infants in NZ weighing at least 400 grams at 89 delivery and born to women who were eligible for the NZ Ministry of Health (MoH)-funded, 90 national-level vaccination program in 2013 (that is, between 28-38 weeks gestation). Infants 91 were followed from birth up to one year of age (Figure 1.) . 92
The independent binary variable was exposure to Tdap during the mother's pregnancy. 93
Study outcomes 94
The study outcomes were prioritized according to the categories presented in the assessment 95 of vaccine safety in pregnant women, as defined by WHO and Brighton Collaboration 96 taskforce, and termed 'priority outcomes', 'outcomes', and 'suggested outcomes' [17] . We 97 used these outcomes as a guide and linked them to International Classification of Disease 10, 98
Australian Modification (ICD-10-AM) codes from relevant chapters A, B, E, F, G, J, P, Q, R 99 and Z to identify outcomes potentially associated with exposure to maternal Tdap 100
vaccination. 101
Each outcome variable is dichotomous, with possible values of yes or no. Where an infant 102 experienced the same outcome on multiple occasions during the study period, only the first 103 episode was considered. Priority outcomes were stillbirth, perinatal death, neonatal death, 104 infant death, preterm birth, small for gestational age (SGA), congenital anomalies (major and 105 minor), asphyxia, infection, and sudden infant death syndrome. Other outcomes with 106 significant findings are also reported. We included all codes across 99 possible diagnosis 107 fields except the Q-codes (congenital anomalies) where only the primary codes were used. 108
Additional covariates include demographic and clinical characteristics and the model of care 109 variable (midwife, obstetrician, general practitioner). 110
Data sources 111
Our data sources for this study have been previously described in detail [16] . They consisted 112 of: the National Health Index Database of demographic information; National Minimum Data 113
Set of all hospital discharges in NZ following inpatient episodes of care; Mortality Data Set 114 of underlying causes of all deaths registered in NZ, including fetal deaths (stillbirths); 115 National Maternity Collection of data on primary maternity services and inpatient and day-116 patient health event data from nine months before and three months after a birth for mothers 117 and infants; and the Immunisation Subsidies Collection of data on the fee-for-service 118 payments made to general practitioners for providing government-funded immunisations. 119
Statistical methods 120
For all infants, follow-up began at birth and infants were censored at the first event outcome 121 of: death, first birthday, or loss to follow-up (no record in any of the data sources). 122
Demographics and clinical characteristics of infants and mothers were first summarised 123 descriptively, overall and by infants who did and did not have fetal exposure to Tdap. 124
Continuous variables were described as mean, standard deviation (SD), median and inter-125 quartile range (Q1, Q3). Categorical variables were described as frequency and percentage. 126
Each reported outcome (with at least one event) was next described quantitatively with 127 frequencies and incidence rates, for exposed and unexposed infant groups separately. The 128 median and interquartile range (Q1, Q3) of infants' age at the time of each outcome was also 129 reported. 130
The relationship between fetal exposure to Tdap and infant outcomes were investigated using 131 adjusted regression models appropriate to the distribution of outcome. Adjusted regression 132 analyses accounted for pre-defined confounding variables and were used to support the main 133 conclusions. Each model was adjusted for: birth status (single live birth, other birth); 134 maternal ethnicity (Māori, Pacific, Asian, NZ European or other); NZ Deprivation Index 135 2013 (deciles grouped into quintiles); maternal age (in years); history of antenatal care (total 136 number of lead maternity carer visits); maternal body mass index (kg/m2); history of chronic 137 disease (yes, no); parity (0, 1+); model of care (District Health Board (DHB), midwife, 138 obstetrician/general practitioner, no lead maternity carer/other); and influenza vaccination 139 (yes, no) during the same pregnancy. Outcomes were excluded if the proportion of events 140 was <0.1% in either exposed or unexposed group, or the number of events in the exposed 141 group was <10. 142
Continuous outcomes (birthweight and Apgar score at 5 minutes after birth) were analysed 143 using linear regression models. The effect of fetal Tdap exposure was estimated as mean 144 difference with 95% confidence intervals. Those outcomes diagnosed at delivery with no 145 follow-up time were considered as a binary variable and analysed using logistic regression 146 models. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported accordingly. An 147 OR of <1 indicated lower odds of having the outcome with fetal exposure to Tdap and was 148 statistically significant if the CI didn't include 1. 149
Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, 150 USA). All statistical tests were two-sided at 5% significance level (p <0.05). 151
Results 152

Study cohort 153
There were a total of 69,389 eligible infants in the cohort. Of these, 8,299 infants were born 154 to 8,178 mothers exposed to Tdap (12%) (Figure 1 ). 155 Of infants born to women eligible to receive the vaccine, 51.2% were male. Infants of 161 European ethnicity comprised 67.0% of the vaccine-exposed group, while infants of Māori 162 ethnicity comprised 13.2%. The deprivation quintile of exposed infants ranged between 163 20.4% and 21.7% for the first four deprivation quintiles. The most deprived quintile 164 contributed 15.2% of exposed infants (Table 1) . 165
The effect of maternal Tdap on hospital-related infant outcomes diagnosed at birth, on 166 eligible maternities, by Tdap exposure are summarised in Tables 2 and 3 . 167 Unexposed N % N % N % Apgar score at 5 minutes after birth Mean (SD) 9.5 (0.9) 9.5 (0.9) 9.5 (0.9) Median (Q1,Q3) 10.0 (9.0,10.0) 10.0 (9.0,10.0) 10.0 (9.0,10.0)
Poor (Apgar 1-3) 17 0.2 116 0.2 133 0.2 Moderate concern (Apgar 4-6) 109 
Events of delivery 195
There were insufficient number of cases in the vaccine-exposed group to assess the 196 association between Tdap exposure and stillbirth (n=9); extreme (n=0) and very preterm birth 197 (n=9), and extreme (n=0) and very low birth weight (n=9). 198
We found a reduced risk associated with exposure to vaccine for moderate to late preterm 199 birth (OR 0.83; 95% CI [0.73, 0.95]). 200
Physical examination and anthropometric measurements 201
There were insufficient observations available to allow examination of the effect of Tdap on 202 extreme low birth weight (LBW) and very LBW. 203 There was no mean difference in Apgar score between vaccine-exposed and unexposed 204 groups (Table 3) . A small but significantly higher mean birthweight was observed in the 205 vaccine-exposed group with a mean difference of 35.59g (95% CI [21.39, 49.78] 
Congenital anomalies 210
Two congenital anomalies that had enough cases to include in the regression models were 211 deformities of feet and ankyloglossia (tongue-tie). There was no association with deformities 212 of feet (OR=0.963; 95% CI [0.61, 1.52]). There was an increased odds associated with 213 ankyloglossia (OR=1.241; 95% CI [1.04, 1.47]). Among the infants in the restricted cohort 214 (eligible to receive the vaccine) born to mothers eligible to receive Tdap, there were three 215 infants in the cohort with microcephaly, none was born to mothers exposed to Tdap. There 216 were insufficient observations in both the exposed and unexposed groups to explore other 217 congenital anomalies 218 Neonatal conditions classified by organ system 219 There was one other infant outcome not elsewhere described that was significantly associated 234 with exposure to Tdap, neonatal erythema toxicum. After adjustment the association r 235 emained significant (OR=1.66; 95% CI [1.16, 2.37]). 236
Infant death 237
There were insufficient events (n=4) in the exposed group of the restricted cohort to allow 238 examination of the effect of Tdap on infant death. 239
Discussion
This study sought to examine the safety for the infant after their mothers received Tdap 241 during the pregnancy. We examined the difference in rates of key outcomes between those 242 infants exposed and not exposed. Among the outcomes we found a reduced risk for moderate 243 to late preterm birth, LBW, SGA, LGA, respiratory distress syndrome, transient tachypnea of 244 newborn, tachycardia or bradycardia, haemolytic diseases, other neonatal jaundice, anaemia, 245 syndrome of infant of mother with gestational diabetes, and hypoglycemia in infants born to 246 vaccinated mothers. There was no association between maternal Tdap and stillbirth, infant 247
Apgar score at 5 minutes after birth, microcephaly, asphyxia, sepsis or infection, or hypoxic 248 ischemic encephalopathy. Infant exposure to Tdap during pregnancy was associated with a 249 higher mean birthweight (not clinically significant) and higher odds for ankyloglossia and 250 neonatal erythema toxicum diagnoses. There were insufficient observations to allow 251 examination of the effect of Tdap on extreme preterm and very preterm birth, and infant 252 death. Overall, we found no outcomes of concern associated with the administration of Tdap 253 during pregnancy. 254
Interpretation 255
Since the implementation of maternal Tdap programmes internationally there are limited data 256 on infants beyond birth outcomes. Most recently a Vaccine Safety Datalink (VSD) study 257 assessed 413,034 live births from 2004 to 2014 for the risk of hospitalisation and showed no 258 overall increased risk (adjusted OR=0.94; 95% CI [0.88, 1.01]) or death (adjusted OR=0.44; 259 95% CI [0.17, 1.13]) in the first six months of life associated with maternal pertussis [18] . 260
While we did not measure overall hospitalisation, our findings support this study. 261
We found no increased risk for stillbirth among our cohort of infants exposed to maternal 262 Tdap, consistent with other cohort studies [19, 20] from Texas, USA and the UK. While we 263 had insufficient observations for infants born extremely preterm or very preterm, we found no 264 increased risk for moderate to late preterm birth. The previous evidence regarding the 265 relationship between Tdap vaccination and preterm birth is mixed. Several VSD studies have 266 found no relationship between Tdap vaccination during pregnancy and preterm birth [21, 22] . 267
The Texas-based study reported a non-significant trend towards a protective effect against 268 preterm birth (>37 weeks) with an adjusted OR for preterm delivery of 0.68 (95% CI: 0.45, 269 1.03)) [23] , and a retrospective cohort study found infants from unvaccinated mothers were 270 more likely to be born preterm (<37 weeks), 6% compared with 12% (p=0.001) [19] . 271
While we had insufficient observations available to allow examination of the effect of Tdap 272 on extreme LBW and very LBW, we found a reduced risk for LBW associated with exposure 273 to Tdap in pregnancy. In the Texas retrospective record review study, the adjusted OR for 274 LBW was 0.76 (0.51-1.14) and very LBW was 0.24 (0.05-1.20) [23] . Likewise a VSD study 275 found no association with LBW with an adjusted RR of 0.92 (0.78-1.09) [22] . In contrast the 276
Texan study found greater risk for lower birthweights among decliners for Tdap in the third, 277 fifth and tenth percentiles (p=0.004, 0.002, and 0.032 respectively) [19] . 278
We found a significant association with reduction in SGA, in line with a maternal influenza 279 study in which the protective effect remained even after consideration of time-dependent 280 biases and confounding from baseline [24] . Unlike preterm birth, for which the protective 281 effect of the vaccine disappeared after adjustments, the associations between vaccination and 282 SGA remained consistent in all analytical approaches [24] . Previous published studies have 283 not shown any association between maternal Tdap vaccination and SGA [21] [22] [23] . Our finding 284 of no association between Tdap and 5-minute Apgar score is consistent with other studies 285 [19, 26, 23] . 286
While we examined many birth defects, all but two were too rare for analysis. Other studies 287 have not identified any increased risk for birth defects associated with maternal Tdap [19, 288 23 ]. Due to the increased cases of microcephaly reported in Brazil and their temporal 289 association with the recommendations for maternal Tdap we specifically assessed this as an 290 outcome. As with a VSD analysis that assessed this [25], we found no association between 291 maternal Tdap and microcephaly, with no cases in the Tdap-exposed group. 292
While most of our outcomes had a reduced risk or no association with maternal Tdap, we did 293 find increased odds of ankyloglossia and neonatal erythema toxicum diagnoses among infants 294 born to vaccinated mothers. Both are likely a result of residual confounding, or spurious 295 association to the large number of endpoints. In NZ, both the diagnosis and management of 296 ankyloglossia is controversial with opposing views on the need for treatment and a strong 297 link to the diagnosis and management approaches for lactation disorders. The reported 298 incidence in NZ has increased more than five-fold between 2007 and 2013 with variability in 299 rates of diagnosis and management by region, ethnicity and socioeconomic group. This 300 suggests an inconsistent diagnostic approach, which therefore impacts the reliability of these 301 results. Erythema toxicum is a common rash in neonates and a diagnosis is strongly linked to 302 health-seeking behaviour. We did not consider either of these outcomes to be related to 303 maternal Tdap. 304
While we adjusted for important confounding variables, including maternal age, ethnicity, 305 socioeconomic status, ANC history, BMI, history of chronic disease, and parity, there may be 306 residual confounding due to important variables not being included in administrative health 307 datasets, such as maternal educational level or other provider/patient characteristics. For 308 example, provider recommendation is an important predictor of a woman receiving Tdap 309 vaccination during pregnancy [26] . Providers that recommend Tdap vaccination during 310 pregnancy are likely to have other differences, such as the characteristics of their patients, 311 type of patient selection and patient care. Measurement error and misclassification of binary 312 confounders can also contribute to residual confounding. Further, we examined many 313 exposures and did not consider confounders on an outcome-by-outcome basis. This analysis 314 approach may have contributed to residual confounding leading to biased estimates. 315
There are other limitations of health administrative datasets. The NZ National Minimum Data 316
Set is limited to hospital inpatient diagnostic codes for which the validity cannot be assessed, 317
with the risk of a false positive and bias towards the null hypothesis; as such, the incidence 318 rates of adverse infant outcomes may be underestimated. Additionally, a hospitalization 319 diagnosis code does not necessarily reflect an incident outcome, as some outcomes may have 320 occurred or presented earlier in pregnancy and only present in later pregnancy with severity 321 requiring hospitalization. As previously reported [16], we conducted a small validation study 322 of the Tdap exposure variable, comparing and primary healthcare organisation (PHO) data 323 and found the immunisation dataset Tdap exposure had high specificity (98.8-99.7%), but 324 low sensitivity (9-61%) among 22,710 pregnant women across seven PHOs, indicating 64% 325 of pregnant women receiving Tdap were incorrectly classified as unvaccinated in the 326 immunisation dataset. In the current study, differential misclassification of the Tdap exposure 327 could be caused by differential quality of data across PHOs and hospitals and could lead to 328 either over-or under-estimation of the effects of Tdap on neonatal outcomes. This potential 329 exposure misclassification means that study results should be cautiously interpreted. In the 330 current study, we only examined data for the first year after implementation (2013), which 331 led to small numbers of outcomes. In addition, we did not account for infant primary 332 vaccinations in our analysis for the longer-term follow-up period. However, the current 333 approach will allow for repeated analyses in future years using the same databases, which are 334 expected to improve over time.
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